Revolution Medicines Inc. (RVMD)
Revolution Medicines' experimental cancer pill helps improve survival in late-stage study
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-stage trial.
Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial
Revolution Medicines says its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% versus chemotherapy.
Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer
Revolution Medicines expects to soon report results from a Phase 3 trial of its daily pill daraxonrasib for pancreatic cancer. Former Republican Sen.
Revolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
General Atlantic L.P. Acquires New Position in Revolution Medicines, Inc. $RVMD
General Atlantic L.P. acquired a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,474,428 shares of the company's stock, valued at approximately $115,556,000. Revolution Medicines comprises about 3.5% of General Atlantic L.P.'s investment portfolio,
Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer
Revolution Medicines stock tanks after a WSJ report said Merck has withdrawn from buyout talks over price.
Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle
Revolution Medicines (RVMD) remains a "Strong Buy", driven by advanced RAS [ON] inhibitor programs and robust clinical progress, notably with Daraxonrasib. Company's phase 3 RASolute-302 trial in metastatic PDAC RAS-mutant patients is a major catalyst, with data expected in 2026 and significant expansion potential. Buyout interest from major pharma, including rumored $28–32B bids, underscores RVMD's strategic value and enhances upside optionality.
Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.
Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.
